![Delayed market entry for generic buprenorphine patches could have cost NHS £500,000, study concludes - The Pharmaceutical Journal Delayed market entry for generic buprenorphine patches could have cost NHS £500,000, study concludes - The Pharmaceutical Journal](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/Transdermal-pain-relief-patch-SPL19.png)
Delayed market entry for generic buprenorphine patches could have cost NHS £500,000, study concludes - The Pharmaceutical Journal
![Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis | BMJ Open Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/9/8/e026817/F3.large.jpg)
Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis | BMJ Open
![Butrans® (buprenorphine) Transdermal System CIII | What is Butrans® ( buprenorphine) Transdermal System CIII? Butrans® (buprenorphine) Transdermal System CIII | What is Butrans® ( buprenorphine) Transdermal System CIII?](https://www.butrans.com/static/chart-what-is-butran-mobile-320c228561e876d45b894b0337b55485.png)